Skip to main content

Branded Legacy Inc. Unveils Cutting-Edge GMP Facility to Accelerate Life-Saving Inhaled Naloxone Development

Written by Customer Service on . Posted in Public Companies.

BioLegacy’s New Vancouver Hub Drives Innovation in Opioid Crisis Solutions with Unmatched Manufacturing and Research Capabilities

VANCOUVER, British Columbia, Sept. 23, 2025 (GLOBE NEWSWIRE) — via IBN – BioLegacy Evaluative Group, Inc., a wholly-owned subsidiary of Branded Legacy Inc. (OTC: BLEG) and an emerging leader in life sciences innovation, proudly announces the official opening of its state-of-the-art 22,000-square-foot Good Manufacturing Practice (GMP) facility in Vancouver, Canada. This milestone, following the recent acquisition of the facility, establishes BLEG as a leader in developing innovative, low-cost inhaled naloxone devices to combat the escalating opioid overdose crisis.

The new facility serves as BioLegacy’s central hub for research, development, and production, building on Branded Legacy’s strategic acquisition of BioLegacy Evaluative Group and partnerships with McMaster University and Stanford University’s Dr. Eran Bendavid. These collaborations, combined with the facility’s advanced infrastructure, enable BLEG to accelerate the development of safe, effective, and accessible overdose-reversal solutions.

“Our new facility is the foundation for BioLegacy’s mission to deliver affordable, accessible overdose-reversal solutions at scale,” said CEO Amin Janmohamed. “By combining academic partnerships with state-of-the-art infrastructure, we are uniquely positioned to translate scientific breakthroughs into life-saving products.”

Facility Highlights

  • State-of-the-Art GMP Facility – Built to global pharmaceutical standards, ensuring scalability and long-term value.
  • Advanced ISO Class 7 & 8 Cleanrooms – Engineered for superior, compliant production across diverse product lines, maintaining strict particle limits (=352,000 particles/m³ =0.5 µm, =83,200 =1 µm, and =2,930 =5 µm in ISO 7 spaces) to ensure exceptional quality.
  • High-Containment Capabilities: Equipped to safely handle potent, hazardous, and controlled substances manufacturing.
  • Integrated Laboratory Systems: In-house testing and validation streamline development and reduce costs.
  • Regulatory Expertise: On-site teams with Health Canada and FDA experience facilitate smooth product approvals.

Dr. Kristian Thorlund, Executive Chair of BLEG, emphasized, “Dealing with the opioid epidemic means bringing devices and products to the populations using extremely hazardous materials. It is imperative that the products we develop can be used safely to both counter-act hazardous materials and work to minimize harms associated with them. These new facilities open up an enormous scientific capability for us.”

A virtual tour led by Dr. Thorlund, showcasing the facility’s advanced capabilities, is now available for stakeholders at https://youtu.be/pTNw2PxE2fU

Strategic Impact

The facility, dedicated initially to BioLegacy’s inhaled naloxone program, enhances the company’s patented intranasal naloxone delivery device, improving accessibility and dosing precision for opioid overdose treatment. Its versatile infrastructure also supports future pipeline expansion, including nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions.

About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group Inc. is a life sciences company dedicated to developing innovative therapies and devices addressing urgent global health challenges. With strategic partnerships at McMaster University and Stanford University, and a newly acquired GMP-compliant manufacturing facility, BLEG is positioned to deliver scalable, cost-effective solutions in areas of high unmet need.

About Branded Legacy, Inc.
Branded Legacy, Inc. (OTC: BLEG) is a holdings company focused on health and wellness, developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. Through its subsidiary, BioLegacy Evaluative Group, and strategic partnerships with McMaster University and Stanford University, Branded Legacy leverages cutting-edge research and advanced manufacturing to deliver transformative healthcare solutions.

Investor Relations:
Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.